INC Research Holdings, Inc. (SYNH)
(Delayed Data from NSDQ)
$47.27 USD
+0.56 (1.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.27 USD
+0.56 (1.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Syneos Health (SYNH) New Partnership to Enhance Clinical Trials
by Zacks Equity Research
Syneos Health (SYNH) new partnership will extend the company's mission to boost research and enable universal patient and provider access with clinical research services.
Why Is Syneos Health (SYNH) Up 4.1% Since Last Earnings Report?
by Zacks Equity Research
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Syneos Health (SYNH) Posts In-Line Q4 Earnings, Margins Up
by Zacks Equity Research
Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.
Syneos Health (SYNH) Matches Q4 Earnings Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 0.00% and 0.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Buys Illingworth Research, Expands CRO Base
by Zacks Equity Research
Syneos Health (SYNH) is currently working on bringing greater flexibility to each customer study, based on data, people, process and technology.
Syneos Health's (SYNH) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Syneos Health (SYNH).
Is Syneos Health (SYNH) a Good Value Investor Stock Now?
by Zacks Equity Research
Let's see if Syneos Health (SYNH) stock is a good choice for value-oriented investors right now from multiple angles.
Here's Why You Should Invest in Syneos Health (SYNH) Now
by Zacks Equity Research
Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery in the Clinical Solutions segment and strategic partnerships.
New Strong Buy Stocks For November 17th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
1Life Healthcare (ONEM) in Focus: Stock Moves 6.3% Higher
by Zacks Equity Research
1Life Healthcare (ONEM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Syneos Health (SYNH) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.
Syneos Health (SYNH) Tops Q3 Earnings Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 15.56% and -1.92%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syneos Health Banks on Essential Therapies Amid Coronavirus Woe
by Zacks Equity Research
Syneos Health's (SYNH) over 70% of clinical businesses comprise essential therapeutic areas that are experiencing reduced impacts of coronavirus outbreak.
Syneos Health (SYNH) Down 8.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Syneos Health-Idorsia Collaborate to Launch Daridorexant in US
by Zacks Equity Research
Syneos Health (SYNH) inks deal with Idorsia to commercialize the treatment for insomnia in the United States.
Syneos Health (SYNH) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Syneos Health (SYNH) wins 35 COVID-19 related projects through the second quarter.
Syneos Health (SYNH) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 20.83% and 0.92%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Syneos Health (SYNH) Q2 Earnings Expected to Decline
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invitae (NVTA) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Invitae (NVTA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Senseonics Holdings (SENS) Catches Eye: Stock Jumps 5.7%
by Zacks Equity Research
Senseonics Holdings (SENS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Allscripts (MDRX) Looks Good: Stock Adds 9.1% in Session
by Zacks Equity Research
Allscripts (MDRX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
10x Genomics (TXG) Looks Good: Stock Adds 6.2% in Session
by Zacks Equity Research
10x Genomics (TXG) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Syneos Health (SYNH) Up 9.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down
by Zacks Equity Research
The coronavirus impact results in inaccessibility of several of Syneos Health's (SYNH) clinical trial sites.